AR129904A2 - Cepas de alto rendimiento del virus de la fiebre amarilla con una propagación incrementada en las células - Google Patents
Cepas de alto rendimiento del virus de la fiebre amarilla con una propagación incrementada en las célulasInfo
- Publication number
- AR129904A2 AR129904A2 ARP230101826A ARP230101826A AR129904A2 AR 129904 A2 AR129904 A2 AR 129904A2 AR P230101826 A ARP230101826 A AR P230101826A AR P230101826 A ARP230101826 A AR P230101826A AR 129904 A2 AR129904 A2 AR 129904A2
- Authority
- AR
- Argentina
- Prior art keywords
- nucleic acid
- yellow fever
- fever virus
- mutation
- acid sequence
- Prior art date
Links
- 241000710772 Yellow fever virus Species 0.000 title abstract 5
- 229940051021 yellow-fever virus Drugs 0.000 title abstract 5
- 150000007523 nucleic acids Chemical group 0.000 abstract 7
- 208000003152 Yellow Fever Diseases 0.000 abstract 6
- 230000035772 mutation Effects 0.000 abstract 5
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 108020004705 Codon Proteins 0.000 abstract 3
- 101710188653 Non-structural protein 4b Proteins 0.000 abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 3
- 241000700605 Viruses Species 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 229940024606 amino acid Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 238000004321 preservation Methods 0.000 abstract 1
- 230000003362 replicative effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
- 210000002845 virion Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C12N2770/24164—Methods of inactivation or attenuation by serial passage
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Una vacuna inactiva y no replicativa que comprende viriones completos, un virus de la fiebre amarilla (FA) inactivado por medios químicos, mediante el uso de un método que asegura la preservación de los epitopes neutralizadores críticos. El virus de la fiebre amarilla ha sido adaptado para propagarlo en células, de modo de obtener mayores rendimientos que los que se obtendrían con virus no adaptados. Métodos para prevenir infecciones del virus de la fiebre amarilla. Reivindicación 1: Una cepa de virus de la fiebre amarilla modificada YF 17D, caracterizada porque comprende una secuencia de ácido nucleico que tiene al menos una mutación de ácido nucleico respecto de la secuencia de ácido nucleico de la cepa de virus de la fiebre amarilla YF 17D, donde dicha al menos una mutación de ácido nucleico es una mutación en la secuencia de ácido nucleico que codifica la proteína no estructural 4B comprende una mutación en el codón del aminoácido correspondiente a la posición 113 de una proteína no estructural 4B SEQ ID Nº 14 que resulta en un cambio de AUA a AUG. Reivindicación 2: La cepa de virus de la fiebre amarilla modificada de acuerdo con la reivindicación 1, caracterizado porque la mutación de ácido nucleico en el codón del aminoácido en la posición 113 de una proteína no estructural 4B da como resultado un cambio de codón, de isoleucina a treonina. Reivindicación 3: El virus de la fiebre amarilla modificado de acuerdo con la reivindicación 2, caracterizado porque comprende un ácido nucleico de SEQ ID Nº 12 y/o una secuencia de aminoácidos de SEQ ID Nº 8.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2010/043010 WO2011014416A2 (en) | 2009-07-31 | 2010-07-23 | High yield yellow fever virus strain with increased propagation in cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR129904A2 true AR129904A2 (es) | 2024-10-09 |
Family
ID=45497513
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100224A AR079970A1 (es) | 2010-07-23 | 2011-01-24 | Cepas de alto rendimiento del virus de la fiebre amarilla con una propagacion incrementada en las celulas |
| ARP230101826A AR129904A2 (es) | 2010-07-23 | 2023-07-12 | Cepas de alto rendimiento del virus de la fiebre amarilla con una propagación incrementada en las células |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100224A AR079970A1 (es) | 2010-07-23 | 2011-01-24 | Cepas de alto rendimiento del virus de la fiebre amarilla con una propagacion incrementada en las celulas |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2596098B1 (es) |
| AR (2) | AR079970A1 (es) |
| BR (1) | BR112012001553B1 (es) |
| CA (1) | CA2768866C (es) |
| TR (1) | TR201815652T4 (es) |
| WO (1) | WO2012011969A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014031480A1 (en) * | 2012-08-24 | 2014-02-27 | Xcellerex, Inc. | Virus purification and formulation process |
| EP3549603A1 (en) * | 2018-04-06 | 2019-10-09 | Sanofi Pasteur | Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same |
| DE102022114042A1 (de) | 2022-06-02 | 2023-12-07 | Gehring Technologies Gmbh + Co. Kg | Vorrichtung und Verfahren zum Ausrichten und/oder Maskieren von Steckspulen |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7227011B2 (en) * | 1998-06-04 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
| US20040259224A1 (en) * | 2002-05-31 | 2004-12-23 | Farshad Guirakhoo | Tetravalent Dengue vaccines |
| WO2004009764A2 (en) * | 2002-07-19 | 2004-01-29 | Board Of Regents, The University Of Texas System | Methods and compositions concerning altered yellow fever virus strains |
| WO2005117958A1 (en) * | 2004-05-28 | 2005-12-15 | Glaxosmithkline Biologicals S.A. | Vaccine compositions comprising virosomes and a saponin adjuvant |
| CA3150333A1 (en) * | 2009-07-31 | 2011-02-03 | Pnuvax Inc. | High yield yellow fever virus strain with increased propagation in cells |
-
2011
- 2011-01-24 AR ARP110100224A patent/AR079970A1/es active IP Right Grant
- 2011-01-25 WO PCT/US2011/022347 patent/WO2012011969A1/en not_active Ceased
- 2011-01-25 BR BR112012001553-2A patent/BR112012001553B1/pt active IP Right Grant
- 2011-01-25 CA CA2768866A patent/CA2768866C/en active Active
- 2011-01-25 EP EP11809985.2A patent/EP2596098B1/en active Active
- 2011-01-25 TR TR2018/15652T patent/TR201815652T4/tr unknown
-
2023
- 2023-07-12 AR ARP230101826A patent/AR129904A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2596098A1 (en) | 2013-05-29 |
| EP2596098A4 (en) | 2014-01-22 |
| EP2596098B1 (en) | 2018-09-26 |
| WO2012011969A1 (en) | 2012-01-26 |
| BR112012001553A2 (pt) | 2020-07-21 |
| CA2768866A1 (en) | 2012-01-26 |
| BR112012001553B1 (pt) | 2021-12-07 |
| TR201815652T4 (tr) | 2018-11-21 |
| CA2768866C (en) | 2018-07-24 |
| AR079970A1 (es) | 2012-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR129904A2 (es) | Cepas de alto rendimiento del virus de la fiebre amarilla con una propagación incrementada en las células | |
| CO2018005265A2 (es) | Vacunas de ácido nucleico para el virus varicela-zóster | |
| CR20150170A (es) | Vacunas de inmersión subunidad para peces | |
| AR079767A1 (es) | Antigeno ndv (virus de la enfermedad de newcastle) recombinante y usos del mismo | |
| MX383596B (es) | Moleculas biespecificas que son inmunorreactivas con celulas efectoras inmunes que expresan un receptor activador y un antigeno expresado por una celula infectada por un virus y usos de las mismas. | |
| CR20140189S (es) | Vacunas y metodos para crear una vacuna para inducir la inmunidad a todos los serotipos del virus del dengue | |
| MX358883B (es) | Aumentar el rendimiento de particulas similares a virus en plantas. | |
| CO7461133A2 (es) | Parvovirus 5a porcino, métodos de uso y vacuna | |
| CL2017003224A1 (es) | Vacuna contra el virus de la fiebre aftosa (fmdv) de virus vaccinia ankara modificado (mva) recombinante | |
| MX363464B (es) | Vacunas contra influenza h5. | |
| WO2011014416A3 (en) | High yield yellow fever virus strain with increased propagation in cells | |
| CL2021003211A1 (es) | Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018) | |
| BR112021012496A2 (pt) | Enterovírus adaptado bem como seu método e processo de adaptação, sequências de nucleotídeo e aminoácido, método para inativar enterovírus e composição imunogênica | |
| AR108014A1 (es) | Vacuna universal para enfermedades virales y método de vacunación | |
| PE20170429A1 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
| CO7461135A2 (es) | Parvovirus porcino 5b, métodos de uso y vacuna | |
| CL2012000783A1 (es) | Proceso para mejorar la eficacia de proteccion metodo para inducir una respuesta inmune contra el virus del dengue que comprende vacunas de dna y virus quimericos 17d; composicion vacunal que comprende vacunas de dna contra los cuatro serotipos del virus dengue y virus quimericos comprendiendo el virus vacunal de fiebre amarilla; plasmido recombinante conteniendo el gen de la proteína e. | |
| AR067439A1 (es) | Virus quimericos antigenicos de virus de encefalitis de st. louis/virus dengue tipo 4 | |
| MX2019001919A (es) | Vacunas virales. | |
| AR085800A1 (es) | Vacuna de rinitis equina | |
| CL2010001400A1 (es) | Procedimiento para detectar el virus de la necrosis pancreatica infecciosa (ipnv) que comprende la amplificacion de fragmento codificante de vp2 mediante rt-pcr y digestion con enzimas de restriccion con el fin de detectar cepas atenuadas y virulentas de ipnv. | |
| BR112022003474A2 (pt) | Vacinas do vírus da hepatite b | |
| BR112019008584A2 (pt) | vacinas de mosaico para vírus de doença de pé-e-boca de sorotipo a | |
| BR112021026502A2 (pt) | Vírus de vacina de síndrome reprodutiva e respiratória porcina | |
| AR115070A1 (es) | Células madre que comprenden un virus vacuna quimérico sintético y métodos para su uso |